- Poster #5915: Three-dimensional (3-D) Multiplex Imaging of Biomarkers in Tumor Tissue
(posted: Apr, 2017)
Clearlight presented research data at the 2017 American Association for Cancer Research (AACR) annual meeting. Includes a link to the poster with the full presentation.
- ClearLight Presents Data on the Multiplex 3D Imaging of the Tumor Microenvironment
(posted: Mar, 2017)
ClearLight announced today that it will present data at the 2017 American Association for Cancer Research meeting in Washington DC on Wednesday, April 5, 2017, 8:00 AM-12:00 PM in the Convention Center Halls A-C, poster session 43, board number 27.
- ClearLight Diagnostics Raises $3.5M in Series B Funding
(posted: Dec, 2016)
Clearlight has completed a $3.5M Series B financing round. The financing will go towards the continued technology platform and applications development using the CLARITY technology and deep imaging with COLM Light Sheet Microscopy.
ClearLight Diagnostics to Present Data on the Multiplex 3D Imaging of the Tumor Microenvironment in a Variety of Preclinical and Clinical Cancer Models
posted: March 29th, 2017
SUNNYVALE, Calif., March 29, 2017 (PR NEWSWIRE)
ClearLight Diagnostics, LLC, a developer of an automated next generation tissue processing and 3D imaging platform, announced today that it will present data at the 2017 American Association for Cancer Research meeting in Washington DC.
Authors: Sharla L. White, Sarah McCurdy, Laurie J. Goodman
Obtaining high-resolution information from solid tumors, while maintaining the spatial perspective needed to understand the heterogeneous tumor microenvironment, represents a key challenge for preclinical and clinical cancer applications. Utilizing CLARITY and 3D imaging of a variety of mouse and human tissue models, this study established the feasibility of the technology to interrogate and visualize thick tissue (>100µm) with multiplexed biomarkers in 3D. These results implicate CLARITY as a powerful next generation tissue processing technology for profiling the intact tumor microenvironment, eliminating the need to recapitulate this spatial and quantitative information with standard thin section techniques. Future studies will be aimed at automating and validating this process in a variety of clinically relevant cancer models.
ClearLight's poster #5915 will be presented on Wednesday, April 5, 2017, 8:00 AM-12:00 PM in the Convention Center Halls A-C, poster session 43, board number 27.
About ClearLight Diagnostics
ClearLight Diagnostics is a technology development company focused on the discovery, development, and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases with an initial focus in oncology. Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing a product platform based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment. This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.
View the full press release at PR Newswire
For immediate release: Clearlight Diagnostics, LLC.